MUMBAI-BASED Sun Pharmaceutical Industries has welcomed approval by the Therapeutic Goods Administration of its Ilumya (tildrakizumab) for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
The company has confirmed it will launch a patient-support program for people prescribed with Ilumya, offering self-injection training, dose reminders, injection consumables and a support help line.
The above article was sent to subscribers in Pharmacy Daily's issue from 24 Sep 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Sep 18
